A Multicentre Double-blind Study to Compare the Efficacy and Safety of Ondansetron (GR 38032F) Administered Either as a Single Intravenous Dose or a Continuous Infusion in the Prophylaxis of Acute Nausea and Vomiting Induced by Cisplatin-containing Cancer Chemotherapy Regimens, Trial ID S3AM23

A Multicentre Double-blind Study to Compare the Efficacy and Safety of Ondansetron (GR 38032F) Administered Either as a Single Intravenous Dose or a Continuous Infusion in the Prophylaxis of Acute Nausea and Vomiting Induced by Cisplatin-containing Cancer Chemotherapy Regimens, Trial ID S3AM23 | GSK